Warning: The NCBI web site requires JavaScript to function. more...
Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients.
Aktas B, Tewes M, Fehm T, Hauch S, Kimmig R, Kasimir-Bauer S.
Breast Cancer Res. 2009;11(4):R46. Epub 2009 Jul 9.
Related citations
Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells.
Kasimir-Bauer S, Hoffmann O, Wallwiener D, Kimmig R, Fehm T.
Breast Cancer Res. 2012 Jan 20;14(1):R15. [Epub ahead of print]
Isolation of circulating epithelial and tumor progenitor cells with an invasive phenotype from breast cancer patients.
Lu J, Fan T, Zhao Q, Zeng W, Zaslavsky E, Chen JJ, Frohman MA, Golightly MG, Madajewicz S, Chen WT.
Int J Cancer. 2010 Feb 1;126(3):669-83.
Increased levels of active c-Src distinguish invasive from in situ lobular lesions.
Zou D, Yoon HS, Anjomshoaa A, Perez D, Fukuzawa R, Guilford P, Humar B.
Breast Cancer Res. 2009;11(4):R45. Epub 2009 Jul 7.
Assessment of a six gene panel for the molecular detection of circulating tumor cells in the blood of female cancer patients.
Obermayr E, Sanchez-Cabo F, Tea MK, Singer CF, Krainer M, Fischer MB, Sehouli J, Reinthaller A, Horvat R, Heinze G, Tong D, Zeillinger R.
BMC Cancer. 2010 Dec 3;10:666.
Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells.
Fehm T, Hoffmann O, Aktas B, Becker S, Solomayer EF, Wallwiener D, Kimmig R, Kasimir-Bauer S.
Breast Cancer Res. 2009;11(4):R59. Epub 2009 Aug 10.
Molecular detection of telomerase-positive circulating epithelial cells in metastatic breast cancer patients.
Soria JC, Gauthier LR, Raymond E, Granotier C, Morat L, Armand JP, Boussin FD, Sabatier L.
Clin Cancer Res. 1999 May;5(5):971-5.
Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies.
Tewes M, Aktas B, Welt A, Mueller S, Hauch S, Kimmig R, Kasimir-Bauer S.
Breast Cancer Res Treat. 2009 Jun;115(3):581-90. Epub 2008 Aug 5.
Detection of cytokeratin 19, human mammaglobin, and carcinoembryonic antigen-positive circulating tumor cells by three-marker reverse transcription-PCR assay and its relation to clinical outcome in early breast cancer.
Chen Y, Zou TN, Wu ZP, Zhou YC, Gu YL, Liu X, Jin CG, Wang XC.
Int J Biol Markers. 2010 Apr-Jun;25(2):59-68.
Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype.
Sarrió D, Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno-Bueno G, Palacios J.
Cancer Res. 2008 Feb 15;68(4):989-97.
Detection of Survivin-expressing circulating cancer cells in the peripheral blood of breast cancer patients by a RT-PCR ELISA.
Yie SM, Luo B, Ye NY, Xie K, Ye SR.
Clin Exp Metastasis. 2006;23(5-6):279-89. Epub 2006 Nov 3.
Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients.
Raimondi C, Gradilone A, Naso G, Vincenzi B, Petracca A, Nicolazzo C, Palazzo A, Saltarelli R, Spremberg F, Cortesi E, Gazzaniga P.
Breast Cancer Res Treat. 2011 Nov;130(2):449-55. Epub 2011 Feb 5.
Enrichment with anti-cytokeratin alone or combined with anti-EpCAM antibodies significantly increases the sensitivity for circulating tumor cell detection in metastatic breast cancer patients.
Deng G, Herrler M, Burgess D, Manna E, Krag D, Burke JF.
Breast Cancer Res. 2008;10(4):R69. Epub 2008 Aug 7.
Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers.
Tanei T, Morimoto K, Shimazu K, Kim SJ, Tanji Y, Taguchi T, Tamaki Y, Noguchi S.
Clin Cancer Res. 2009 Jun 15;15(12):4234-41. Epub 2009 Jun 9.
Breast cancer stem cell markers - the rocky road to clinical applications.
Dontu G.
Breast Cancer Res. 2008;10(5):110. Epub 2008 Sep 15.
Final Report on Carcinogens Background Document for Formaldehyde.
National Toxicology Program.
Rep Carcinog Backgr Doc. 2010 Jan;(10-5981):i-512.
The epithelial-to-mesenchymal transition and cancer stem cells: a coalition against cancer therapies.
Hollier BG, Evans K, Mani SA.
J Mammary Gland Biol Neoplasia. 2009 Mar;14(1):29-43. Epub 2009 Feb 26. Review.
Circulating tumour cells lacking cytokeratin in breast cancer: the importance of being mesenchymal.
Gradilone A, Raimondi C, Nicolazzo C, Petracca A, Gandini O, Vincenzi B, Naso G, Aglianò AM, Cortesi E, Gazzaniga P.
J Cell Mol Med. 2011 May;15(5):1066-70. doi: 10.1111/j.1582-4934.2011.01285.x.
Detection of circulating tumor cells in breast cancer may improve through enrichment with anti-CD146.
Mostert B, Kraan J, Bolt-de Vries J, van der Spoel P, Sieuwerts AM, Schutte M, Timmermans AM, Foekens R, Martens JW, Gratama JW, Foekens JA, Sleijfer S.
Breast Cancer Res Treat. 2011 May;127(1):33-41. Epub 2010 Apr 9.
Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers.
Deng S, Yang X, Lassus H, Liang S, Kaur S, Ye Q, Li C, Wang LP, Roby KF, Orsulic S, Connolly DC, Zhang Y, Montone K, Bützow R, Coukos G, Zhang L.
PLoS One. 2010 Apr 21;5(4):e10277.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on